# US 2020/0369660 A1 · Pyrimidine compound as jak kinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369660 A1
- Document ID: US20200369660A1
- Status: Published application
- Kind: A1
- Application number: 16/991,268
- Filed: 2020-08-12
- Published: 2020-11-26
- Earliest claimed: 2017-10-27
- Assignees: Theravance Biopharma R&D IP, LLC
- Applicants: Theravance Biopharma R&D IP, LLC
- Inventors: JENNIFER KOZAK; RYAN HUDSON; ROBERT MURRAY MCKINNELL; GARY E.L. BRANDT
- Web page: https://patentgrep.com/patent/US20200369660A1

## CPC

- C07D 451/14: containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/14: for baldness or alopecia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.

## Claims

### Claim at position 1

1-32. (canceled)

### Claim 33

A method of treating atopic dermatitis in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound of formula (I):
or a pharmaceutically-acceptable salt thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein the atopic dermatitis is moderate to severe atopic dermatitis.

### Claim 35 (depends on 33)

The method of claim 33, wherein the atopic dermatitis is mild to moderate atopic dermatitis.

### Claim 36 (depends on 33)

The method of claim 33, wherein the compound of formula (I), or a pharmaceutically-acceptable salt thereof, is administered to the skin of the human.

### Claim 37 (depends on 36)

The method of claim 36, wherein the compound of formula (I), or a pharmaceutically-acceptable salt thereof, is administered in a pharmaceutical composition.

### Claim 38 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is an ointment.

### Claim 39 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a cream.

### Claim 40 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a lotion.

### Claim 41 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a gel.

### Claim 42 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a stick.

### Claim 43 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a spray.

### Claim 44 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a paste.

### Claim 45 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a foam.

### Claim 46 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition is a mousse.

### Claim 47 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition comprises between 0.1 and 10% by weight of compound (I), or a pharmaceutically acceptable salt thereof.

### Claim 48 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition comprises between 0.25 and 5% by weight of compound (I), or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 37)

The method of claim 37, wherein the pharmaceutical composition comprises between 0.05 and 0.5% by weight of compound (I), or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 33)

The method of claim 33, wherein the compound is administered in a freebase form.

### Claim 51 (depends on 33)

The method of claim 33, wherein the method further comprises administering one or more additional therapeutic agents.
